ACTH(4-10) is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
The ligated mRNA-DNA-puromycin library is translated in Red Nova Lysate (Novagen) or E. coli S30 Extract System (Promega), resulting in peptides covalently linked in cis to the encoding mRNA. The in vitro translation can also be done in a PURE (protein synthesis using recombinant elements) system. PURE system is an E. coli cell-free translation system in which only essential translation components are present. Some components, such as amino acids and aminoacyl-tRNA synthases (AARSs) can be omitted from the system. Instead, chemically acylated tRNA can be added into the PURE system. It has been shown that some unnatural amino acids, such as N-methyl-amino acid accylated tRNA can be incorporated into peptides or mRNA-peptide fusions in a PURE system. After translation, the single-stranded mRNA portions of the fusions will be converted to heteroduplex of RNA/DNA by reverse transcriptase to eliminate any unwanted RNA secondary structures, and render the nucleic acid portion of the fusion more stable. This step is a standard reverse transcription reaction. For instance, it can be done by using Superscript II (GIBCO-BRL) following the manufacturer's protocol.
One study reviewed the relative diagnostic value of enzyme and bicarbonate concentrations compared with enzyme output in 363 secretin-CCK tests. The investigators also evaluated the requirement for perfusion markers to accurately quantify volume, and the validity of a shortened sampling time (first 20 minutes). Only 60 percent of volume was recovered with the duodenal aspiration tube, suggesting that marker perfusion to correct for distal loss of secretion is important to accurately quantify volume. Using a trypsin output <50 U/kg/h as the reference standard, measurement of enzyme concentration alone misclassified approximately 10 percent of patients. Use of a shortened collection time misclassified approximately 4 percent of patients. The authors concluded that this was an unacceptably high rate of misclassification and that the standard prolonged collection of fluid using a perfusion marker must be performed to accurately measure exocrine function.
==== Pallotta and Celluloid Dreams ==== Tommy Pallotta, who produced the film adaptation of Dick's novel A Scanner Darkly, said in an interview in July 2006 that he "still [had] the option for Ubik" and wanted to "make a live action feature from it". In 2007, Dick's daughter, Isa Dick Hackett, said that the film adaptation of Ubik was at an advanced stage of negotiations. In May 2008, the film was optioned by Celluloid Dreams, to be produced by Hengameh Panahi for Celluloid Dreams and Isa Dick Hackett for Electric Shepherd Productions. It was slated to enter production in early 2009, but never materialised.
=== Use after MDMA === MDMA is an empathogenic-entactogenic and serotonergic psychotropic drug used primarily for recreational, though sometimes also therapeutic, purposes. Among users of MDMA, the serotonergic effects of the drug are often of particular interest and concern: After consuming MDMA, serotonin concentrations are greatly reduced in the brain. 5-HTP is necessary for serotonin production and its concentrations in the brain also decrease after taking MDMA.
=== Russian aid to Cuba === On 30 March, a Russian oil tanker, the Anatoly Kolodkin, carrying 100,000 tonnes of crude oil, or 730,000 barrels, arrived in Havana. The Russian shipment could be converted into 250,000 barrels of diesel which could cover Cuban energy demands for 12 and a half days. The Guardian argued that the docking of the Russian tanker signals greater American flexibility in the ability of Cuba to purchase oil from abroad. On 27 May, the Universal, a Russian fuel tanker, failed to reach Cuba, turning around off the coast of Brazil. The vessel itself is subject to U.S. sanctions and some speculate that the ship was interceded by American naval authorities.
Sources: en.wikipedia.org
==== Anaerobic decay ==== In the absence of plentiful oxygen, aerobic bacteria were prevented from decaying the organic matter after it was buried under a layer of sediment or water. However, anaerobic bacteria were able to reduce sulfates and nitrates among the matter to H2S and N2 respectively by using the matter as a source for other reactants. Due to such anaerobic bacteria, at first, this matter began to break apart mostly via hydrolysis: polysaccharides and proteins were hydrolyzed to simple sugars and amino acids respectively. These were further anaerobically oxidized at an accelerated rate by the enzymes of the bacteria: e.g., proteins went through oxidative deamination to amino acids, which in turn reacted further to ammonia and α-keto acids. Monosaccharides in turn ultimately decayed to CO2 and methane. The anaerobic decay products of amino acids, monosaccharides, phenols and aldehydes combined into fulvic acids. Fats and waxes were not extensively hydrolyzed under these mild conditions.
=== Brand collaborations === American fashion brand Denim Tears would be the first brand to collaborate with Clipse, unveiling a Let God Sort Em Out-branded T-shirt in June 2024, a whole year before the album's eventual release; this was in celebration of the brand's fifth anniversary. Further brand collaborations remained unknown until the release of "So Be It" on June 18, 2025, where Clipse would unveil an alternate album package and merchandise line, designed by Japanese artist Verdy. Williams's Billionaire Boys Club line would announce an exclusive black T-shirt on June 21. The company made the T-shirt available at their flagship stores from that date forward, with the shirt releasing online on July 11. Pusha T would begin teasing Clipse-branded Adidas Samba shoes on July 7; they were given an early-access release on July 14. A Carhartt collaboration was announced the following day; it was released alongside the album on July 11, featuring jackets, graphic T-shirts, a hoodie and sweatshirt. Another alternate album package, designed by American artist Josh Sperling, was announced on July 15.
Most RTGs use 238Pu, which decays with a half-life of 87.7 years. RTGs using this material therefore diminish in power output by a factor of 1 – (1/2)1/87.7, or 0.787%, per year. One example is the MHW-RTG used by the Voyager probes. In the year 2000, 23 years after production, the radioactive material inside the RTG had decreased in power by 16.6%, i.e. providing 83.4% of its initial output; starting with a capacity of 470 W, after this length of time it would have a capacity of only 392 W. A related loss of power in the Voyager RTGs is the degrading properties of the bi-metallic thermocouples used to convert thermal energy into electrical energy; the RTGs were working at about 67% of their total original capacity instead of the expected 83.4%. By the beginning of 2001, the power generated by the Voyager RTGs had dropped to 315 W for Voyager 1 and to 319 W for Voyager 2. By 2022, these numbers had dropped to around 220 W. NASA has developed a multi-mission radioisotope thermoelectric generator (MMRTG) in which the thermocouples would be made of skutterudite, a cobalt arsenide (CoAs3), which can function with a smaller temperature difference than the current tellurium-based designs. This would mean that an otherwise similar RTG would generate 25% more power at the beginning of a mission and at least 50% more after seventeen years. NASA hopes to use the design on the next New Frontiers mission.
The risk of breast cancer in women with Turner syndrome (45,XO karyotype) also appears to be significantly decreased, though this could be related to ovarian failure and hypogonadism rather than to genetics. Prostate cancer is extremely rare in gonadectomized transgender women who have been treated with estrogens for a prolonged period of time. Whereas as many as 70% of men show prostate cancer by their 80s, only a handful of cases of prostate cancer in transgender women have been reported in the literature. As such, and in accordance with the fact that androgens are responsible for the development of prostate cancer, HRT appears to be highly protective against prostate cancer in transgender women. The risks of certain types of benign brain tumors including meningioma and prolactinoma are increased with hormone therapy in transgender women. These risks have mostly been associated with the use of cyproterone acetate. Estrogens and progestogens can cause prolactinomas, which are benign, prolactin-secreting tumors of the pituitary gland. Milk discharge from the nipples can be a sign of elevated prolactin levels. If a prolactinoma becomes large enough, it can cause visual changes (especially decreased peripheral vision), headaches, depression or other mood changes, dizziness, nausea, vomiting, and symptoms of pituitary failure, like hypothyroidism.
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
The sequence is Met-Glu-His-Phe-Pro-Gly-Pro, a seven-residue peptide. The first four residues correspond to the ACTH(4-10) fragment, and Pro-Gly-Pro is added at the C-terminus. N-acetylated versions also appear in the literature and differ in mass.